



## Amgen Ventures Overview

Amgen is driven by a desire to transform science through innovation, and in this way to develop important new treatments for grievous illness. We understand that science is a global and collective endeavor, and that many of the scientific breakthroughs of tomorrow will come from early-stage companies.

In 2004, Amgen announced the formation of Amgen Ventures, a corporate venture capital fund designed to provide emerging biotechnology companies with resources to develop pioneering discoveries focused on human therapeutics. Amgen Ventures reflects Amgen's commitment to helping patients through cutting-edge science and is an important component of Amgen's overall outreach strategy.

With an initial commitment of \$100 million, Amgen Ventures intends to invest in early-stage biotechnology companies focused on discovering and developing human therapeutics. The focus of the fund primarily will be in areas of current therapeutic interest to Amgen, but will also include novel modalities with the potential to address targets in both current and emerging therapeutic areas of interest.

Working with Amgen Ventures can offer early stage companies access to Amgen's extensive capabilities while providing Amgen with insight into external research innovations that may pave the way for future collaborations. By bringing capital and access to Amgen's scientific and product development expertise, Amgen Ventures has the potential to help companies meet their early challenges and position them for success.

Amgen Ventures is based in Thousand Oaks and San Francisco but also leverages additional Amgen sites, including Seattle and Cambridge.

### INVESTMENT STRATEGY

Amgen Ventures typically invests up to \$2 to 3 million per round and may invest up to \$10 million per company. We primarily are seeking investments in North America however we do consider investments in Europe and the United Kingdom.

While investments are made in strategic areas of interest to Amgen with the intent to facilitate future business development, the Amgen Ventures portfolio is managed with the goal of financial return.

### THE AMGEN VENTURES TEAM

Janis Naeve, Ph.D., Director  
amgenventures@amgen.com  
805-447-1000

## Amgen Ventures Current Portfolio Companies



Allozyne is focused on developing next generation protein optimization technology through the use of non-natural amino acids.



Calistoga Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing innovative medicines targeting the PI3kinase and related pathways for the treatment of cancer and inflammatory diseases to improve the health of patients.

### DeclImmune Therapeutics

DeclImmune focuses on the innate immune system to exploit natural antibody targets for the development of therapeutics to treat inflammation and autoimmunity.



Epizyme is a biopharmaceutical company that is creating innovative drugs that will provide revolutionary treatments for major diseases based on the profound discoveries emerging from the field of epigenetics.



MiRagen is developing innovative microRNA (miRNA) based therapeutics for cardiovascular and muscle disease.



Mirina Corp. focuses on the generation of novel microRNA (miRNA) therapeutics with improved properties, such as enhanced target selectivity and higher potency.



Theraclone is a privately-held biotechnology company focused on developing novel therapeutic antibodies for the treatment of cancer and infectious disease.



Synovex is developing protein therapeutics to block the effect of cadherin-11 and reduce tissue damage.



TetraLogic Pharmaceuticals is developing oncology therapeutics to unblock the cell death or apoptosis pathway which results in the death of tumor cells.



Trinity Biosystems is developing a unique platform technology to produce a new class of vaccines and enable the oral delivery of protein therapeutics and peptides.



VLST uses its bioinformatics/proteomics platform to identify new targets for the development of novel biologic therapies to treat a variety of immune disorders.



Xori is focused on developing a new technology that enables the evolution and selection of high affinity antibodies specific for virtually any target.